RT Journal Article
T1 Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs
A1 Leira Feijóo, Yago
A1 Domínguez Vivero, Clara
A1 Ameijeira Dávila, Pablo
A1 López Arias, Esteban
A1 Ávila Gómez, Paulo
A1 Pérez Mato, María
A1 Sobrino Moreiras, Tomás
A1 Campos Pérez, Francisco
A1 Blanco Carrión, Juan
A1 Leira Muiño, Rogelio Manuel
K1 Headache
K1 Neurological disorders
K1 Neurology
AB The anti-inflammatory effect of OnabotulinumtoxinA (OnabotA) has been a matter of discussion for many years. In chronic migraine, however, increased pro-inflammatory state is associated with good response to OnabotA. We aimed to investigate whether a mild systemic inflammatory state elicited by a common oral infection (periodontitis) could enhance treatment response to OnabotA. In this study, we included 61 chronic migraineurs otherwise healthy treated with OnabotA of which 7 were poor responders and 54 good responders. Before receiving OnabotA therapy, all participants underwent a full-mouth periodontal examination and blood samples were collected to determine serum levels of calcitonin gene-related peptide (CGRP), interleukin 6 (IL-6), IL-10 and high sensitivity C-reactive protein (hs-CRP). Periodontitis was present in 70.4% of responders and 28.6% of non-responders (P = 0.042). Responders showed greater levels of inflammation than non-responders (IL-6: 15.3 ± 8.7 vs. 9.2 ± 4.7 ng/mL, P = 0.016; CGRP: 18.8 ± 7.6 vs. 13.0 ± 3.1 pg/mL, P = 0.002; and hs-CRP: 3.9 ± 6.6 vs. 0.9 ± 0.8 mg/L, P = 0.003). A linear positive correlation was found between the amount of periodontal tissue inflamed in the oral cavity and markers of inflammation (IL-6: r = 0.270, P = 0.035; CGRP: r = 0.325, P = 0.011; and hs-CRP: r = 0.370, P = 0.003). This report shows that in presence of elevated systemic inflammatory markers related to periodontitis, OnabotA seems to reduce migraine attacks. The changes of scheduled inflammatory parameters after treatment and subsequent assessment during an adequate period still need to be done
PB Springer Nature
YR 2021
FD 2021
LK http://hdl.handle.net/10347/24390
UL http://hdl.handle.net/10347/24390
LA eng
NO Leira, Y., Domínguez, C., Ameijeira, P. et al. Mild systemic inflammation enhances response to OnabotulinumtoxinA in chronic migraineurs. Sci Rep 11, 1092 (2021). https://doi.org/10.1038/s41598-020-80283-4
NO This study was partially supported by a grant from the Spanish Ministry of Economy and Competitiveness—Institute of Health Carlos III (PI15/01578). YL holds a Senior Clinical Research Fellowship supported by the UCL Biomedical Research Centre who receives funding from the NIHR (NIHR-INF-0387) and a research contract with Fundación Instituto de Investigación Sanitaria de Santiago de Compostela (fIDIS). TS (CPII17/00027) and FC (CP14/00154) are recipients of research contracts from Miguel Servet Program of Institute of Health Carlos III
DS Minerva
RD 22 abr 2026